PipelineReview.com10h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
INGELHEIM, Germany I, 2025 I Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)∗ and OXB,ŧ today announce the start ...
PipelineReview.com10h
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
EMERYVILLE, CA, USA I1, 2025 I Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical ...
PipelineReview.com10h
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
REYKJAVIK, Iceland and PARSIPPANY, NJ, USA I1, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: ...
PipelineReview.com10h
Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer
PITTSBURGH, PA, USA I February 20, 2025 I Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as ...
PipelineReview.com10h
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...
PipelineReview.com10h
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales ...
PipelineReview.com10h
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.
PipelineReview.com2d
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy
SAN DIEGO, CA, USA I February 19, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
PipelineReview.com2d
Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites
MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...
PipelineReview.com2d
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
BOSTON, MA, USA I February 19, 2025 I Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered ...
PipelineReview.com2d
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
Preclinical Data Highlight TP-317’s Anti-Inflammatory, Epithelial Barrier-Protective Effects ...
PipelineReview.com3d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
FOSTER CITY, CA, USA I February 18, 2025 I Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions ...